Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Payables (2021 - 2025)

Stoke Therapeutics has reported Payables over the past 5 years, most recently at $4.9 million for Q4 2025.

  • For Q4 2025, Payables rose 97.72% year-over-year to $4.9 million; the TTM value through Dec 2025 reached $4.9 million, up 97.72%, while the annual FY2025 figure was $4.9 million, 97.72% up from the prior year.
  • Payables for Q4 2025 was $4.9 million at Stoke Therapeutics, down from $5.9 million in the prior quarter.
  • Over five years, Payables peaked at $5.9 million in Q3 2025 and troughed at $766000.0 in Q4 2022.
  • A 5-year average of $3.0 million and a median of $2.5 million in 2024 define the central range for Payables.
  • Biggest five-year swings in Payables: plummeted 67.88% in 2022 and later surged 153.53% in 2024.
  • Year by year, Payables stood at $2.4 million in 2021, then plummeted by 67.88% to $766000.0 in 2022, then surged by 121.28% to $1.7 million in 2023, then surged by 47.37% to $2.5 million in 2024, then soared by 97.72% to $4.9 million in 2025.
  • Business Quant data shows Payables for STOK at $4.9 million in Q4 2025, $5.9 million in Q3 2025, and $4.3 million in Q2 2025.